- ISIN
- AU000000TLX2
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 14, 2024
Highlights
- Market Cap
- $3.46B
- Enterprise Value
- $3.87B
- EPS (TTM)
- A$0.12
- PE Ratio
- 127.38
- PEG Ratio
- 0.16
- Total Revenue (TTM)
- A$2.00B
- Gross Profit (TTM)
- A$1.13B
- EBITDA (TTM)
- A$153.71M
- Year Range
- $6.28 - $16.98
- Target Price
- $19.00
- ROA (TTM)
- 2.21%
- ROE (TTM)
- 6.30%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TLX Performance Chart
Telix Pharmaceuticals Ltd (TLX) is up 36.3% since the beginning of the year. At $10 per share, TLX is trading 39.9% below its 52-week high of $17.
Loading charts...
Returns By Period
Telix Pharmaceuticals Ltd (TLX) has returned 36.32% so far this year and -37.71% over the past 12 months.
Telix Pharmaceuticals Ltd
- 1D
- 2.10%
- 1M
- 7.81%
- YTD
- 36.32%
- 6M
- 26.21%
- 1Y
- -37.71%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
TLX Monthly Returns History
Based on dividend-adjusted daily data since Nov 14, 2024, TLX's average daily return is -0.05%, while the average monthly return is -1.20%.
Historically, 40% of months were positive and 60% were negative. The best month was Mar 2026 with a return of +32.0%, while the worst month was Aug 2025 at -29.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.
On a daily basis, TLX closed higher 47% of trading days. The best single day was Feb 20, 2026 with a return of +14.6%, while the worst single day was Aug 28, 2025 at -16.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.80% | -0.41% | 32.00% | 14.94% | -14.27% | 8.27% | 36.32% | ||||||
| 2025 | 20.78% | -3.33% | -6.79% | 3.82% | -2.36% | -5.41% | -15.43% | -29.73% | 0.21% | 11.39% | -6.66% | -24.72% | -51.36% |
| 2024 | 3.15% | -6.63% | -3.69% |
Benchmark Metrics
Telix Pharmaceuticals Ltd has an annualized alpha of -22.47%, beta of 0.92, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 14, 2024.
- This stock participated in 37.03% of S&P 500 Index downside but only -63.77% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -22.47%
- Beta
- 0.92
- R²
- 0.08
- Upside Capture
- -63.77%
- Downside Capture
- 37.03%
Return for Risk
Risk / Return Rank
TLX ranks 19 for risk / return — in the bottom 19% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Telix Pharmaceuticals Ltd (TLX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TLX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.43 | ||
| Sortino ratioReturn per unit of downside risk | -3.20 | ||
| Omega ratioGain probability vs. loss probability | 0.91 | 1.32 | -0.41 |
| Calmar ratioReturn relative to maximum drawdown | -0.61 | 2.46 | -3.06 |
| Martin ratioReturn relative to average drawdown | -0.88 | 10.92 | -11.80 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Telix Pharmaceuticals Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Telix Pharmaceuticals Ltd was 69.37%, occurring on Feb 18, 2026. The portfolio has not yet recovered.
The current Telix Pharmaceuticals Ltd drawdown is 51.22%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -69.37%Feb 2026 | 11mo 28d | — | 1y 3moFeb 2025 - now |
2025 correction2025 | -12.81%Jan 2025 | 1mo 5d | 4d | 1mo 9dDec 2024 - Jan 2025 |
2025 selloff2025 | -9.05%Feb 2025 | 9d | 7d | 16dFeb 2025 - Feb 2025 |
2024 pullback2024 | -8.07%Nov 2024 | 8d | 7d | 15dNov 2024 - Nov 2024 |
2024 pullback2024 | -2.99%Dec 2024 | 3d | 1d | 4dDec 2024 - Dec 2024 |
Drawdown Indicators
| TLX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.37% | -56.78% | -12.59% |
Max Drawdown (1Y)Largest decline over 1 year | -62.12% | -9.10% | -53.02% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -51.22% | -3.21% | -48.01% |
Average DrawdownAverage peak-to-trough decline | -37.10% | -10.71% | -26.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.86% | 2.04% | +40.82% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Telix Pharmaceuticals Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Telix Pharmaceuticals Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TLX, comparing it with other companies in the Biotechnology industry. Currently, TLX has a P/E ratio of 127.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TLX compared to other companies in the Biotechnology industry. TLX currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TLX relative to other companies in the Biotechnology industry. Currently, TLX has a P/S ratio of 2.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TLX in comparison with other companies in the Biotechnology industry. Currently, TLX has a P/B value of 8.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TLX
Add Telix Pharmaceuticals Ltd to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TLX